DCTD Synthetic Chemistry

合成化学实验室(LSC)的建立以临床前为主要目标，为开发治疗计划的癌症药物发现和开发工作以及DCTD-CCR(JDC)联合开发委员会批准的项目提供化学支持。为此，LSC将把其活动重点放在铅优化上，这是新药发现和开发的一个基本和不可或缺的部分。将开发新的合成方法，以有效的先导化合物为基础创建新的类似物，以迭代的方式解决以下药物属性：活性、肿瘤选择性、溶解性、生物利用度、稳定性和ADME/PK，从而改善药物概况。该实验室致力于开发新的相关合成方法，供更广泛的校外社区应用，特别是由DCTD资助的社区。 最近，DCTD与癌症研究中心和NCI主任办公室一起建立了一个名为化学生物学联盟(CBC)的新计划，以促进治疗癌症的新药物的发现和开发。CBC预计将成为一个处于化学生物学和分子肿瘤学前沿的综合研究联盟，将与NCI内部和外部科学界的各种计划合作，建立一个小型生物技术公司规模的迭代癌症药物发现小组，并将新的癌症治疗推进到临床。CBC的目标是专注于肿瘤学中尚未得到满足的治疗需求，这些需求目前没有得到包括制药业在内的私营部门的解决。为了应对这一挑战，并重新确立NCI在国家癌症治疗领域的主要参与者地位，CBC筛查和化学中心以及其他科学团体的成功互动是必要的。为了实现这一目标，LSC已成为CBC化学支持中心，它将与NCI和外部承包商实验室内的各种DCTD中心和项目互动，以促进通过药物化学识别新药发现，最终目标是开发新的临床候选药物。

The Laboratory of Synthetic Chemistry (LSC) has been established with a primary preclinical objective to provide chemistry support to the cancer drug discovery and development efforts of the Developmental Therapeutics Program and the projects approved by the Joint Development Committee of DCTD-CCR (JDC). Towards this end LSC will focus its activities on lead optimization, an essential and integral part of new drug discovery and development. Novel synthetic methodologies will be developed to create new analogs based on the effective lead compounds to improve pharmaceutical profiles by addressing the following drug properties: activity, tumor selectivity, solubility, bioavailability, stability and ADME/PK in an iterative fashion. The laboratory is engaged in developing new relevant synthesis methodologies for applications by the wider extramural community, especially those funded by DCTD. Most recently, DCTD in conjunction with the Center for Cancer Research and the Office of the Director, NCI established a new program called the Chemical Biology Consortium (CBC) to facilitate the discovery and development of new agents to treat cancer. The CBC is expected to be an integrated research consortium at the cutting edge of chemical biology and molecular oncology that will work with various programs within NCI and outside scientific community, establish an iterative cancer drug discovery group on the scale of a small biotechnology concern, and advance new cancer therapy into the clinic. The goal of the CBC is to focus on unmet therapeutic needs in oncology that are not currently addressed by the private sector, including the pharmaceutical industry. To address this challenge and to re-establish NCI as a major player in the national cancer therapeutic arena, successful interaction of CBC Screening and Chemistry centers and other scientific groups is necessary. To achieve this goal, the LSC has become the CBC Chemistry support center that will interact with various DCTD centers and programs within NCI and outside contractor laboratories to facilitate the identification of new drug discoveries through medicinal chemistry with the ultimate goal of developing new clinical candidates.